LncRNA SNHG3 is activated by E2F1 and promotes proliferation and migration of non-small-cell lung cancer cells through activating TGF-β pathway and IL-6/JAK2/STAT3 pathway.
Animals
Carcinoma, Non-Small-Cell Lung
/ genetics
Cell Line, Tumor
Cell Proliferation
/ genetics
E2F1 Transcription Factor
/ genetics
Epithelial-Mesenchymal Transition
/ genetics
Gene Expression Regulation, Neoplastic
/ genetics
Humans
Interleukin-6
/ metabolism
Janus Kinase 2
/ metabolism
Lung Neoplasms
/ genetics
Mice
RNA, Long Noncoding
/ genetics
STAT3 Transcription Factor
/ genetics
Signal Transduction
/ genetics
Transforming Growth Factor beta
/ metabolism
Up-Regulation
E2F1
IL-6/JAK2/STAT3 pathway
NSCLC
SNHG3
TGF-β pathway
migration
proliferation
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
07
05
2019
accepted:
03
09
2019
pubmed:
12
10
2019
medline:
17
12
2020
entrez:
12
10
2019
Statut:
ppublish
Résumé
Recently, long noncoding RNAs (lncRNAs) have been widely reported to play pivotal roles in the regulation of human cancers. Although the oncogenic property of lncRNA small nucleolar RNA host gene 3 (SNHG3) has been revealed in a variety of cancers, functions and regulatory mechanism of SNHG3 in non-small-cell lung cancer (NSCLC) remain to be investigated. In this study, we detected the upregulated expression of SNHG3 in NSCLC tissues as well as cells through quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis. Using Kaplan-Meier analysis, we determined that a high-level of SNHG3 was associated with a low overall survival rate of patients with NSCLC. Through gain and loss of function experiments, we demonstrated that SNHG3 had a significantly positive effect on NSCLC cell proliferation and migration. Mechanistic investigations revealed that SNHG3 was a predicted direct transcriptional target of E2F1. We observed that the transcriptional activation of SNHG3 could be induced by E2F1. To explore the mechanism, rescue experiments were carried out, which revealed that the cotreatment with SB-431542, JSI-124, or JSI-124 + SB-431542 rescued the effects brought by the overexpression of SNHG3 on NSCLC cell proliferation, migration, and epithelial-mesenchymal transition process. Our results suggested that E2F1 activated SNHG3 and promoted cell proliferation and migration in NSCLC via transforming growth factor-β pathway and interleukin-6/janus-activated kinase 2/signal transducer and activator of transcription 3 pathway, which implied that SNHG3 may be a biomarker for the treatment of patients with NSCLC.
Substances chimiques
E2F1 Transcription Factor
0
E2F1 protein, human
0
E2f1 protein, mouse
0
Interleukin-6
0
RNA, Long Noncoding
0
STAT3 Transcription Factor
0
Transforming Growth Factor beta
0
Janus Kinase 2
EC 2.7.10.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2891-2900Informations de copyright
© 2019 Wiley Periodicals, Inc.